A case of mucopolysaccharidosis type VI in Indian family: importance of clinical characteristics, urinary GAG and enzyme assay in diagnosis of mucopolysaccharidosis
DOI:
https://doi.org/10.18203/2349-3291.ijcp20250420Keywords:
Mucopolysaccharidoses, Urinary GAG, ARSB gene, Enzyme assay, Maroteaux-Lamy syndromeAbstract
Mucopolysaccharidosis (MPS) are hereditary progressive disease caused by mutations in genes coding for lysosomal enzymes essential to breakdown GAG. The inadequate degradation process leads to accumulation GAG in lysosome of diverse tissues, which interfere with cell functioning and leads to characteristic patterns of clinical, radiologic and biochemical problems. Patient appears to be healthy at birth and, symptoms start about 2-3 years of age. Clinical characteristics, radiographic findings, and notably enzyme assays have allowed us to make a clear diagnosis in these situations. There are extremely few cases of MPS VI reported in India. Here we are reporting a case of 14 yr. old female patient with a combination of clinical, radiological and biochemical characteristics confirmed as a case of MPS type VI. This example illustrates that atypical clinical symptom, such as growth failure, coarse facial features, and joint difficulties, are key pointers for further investigations linked to MPS disease. However, in low- and middle-income countries, it is difficult to make a definite diagnosis of one of the MPS due to insufficient enzyme assay.
Metrics
References
D’Avanzo F, Zanetti A, De Filippis C, Tomanin R. Mucopolysaccharidosis Type VI, an updated overview of the disease. International Journal of Molecular Sciences. 2021;22(24):13456. DOI: https://doi.org/10.3390/ijms222413456
Celik B, Tomatsu SC, Tomatsu S, Khan SA. Epidemiology of mucopolysaccharidoses update. Diagnostics. 2021;11(2):273. DOI: https://doi.org/10.3390/diagnostics11020273
Soeiro RT, Devon EP, editors. Netter's Pediatrics E-Book: Netter's Pediatrics E-Book. Elsevier Health Sciences. 2022.
Harmatz P, Shediac R. Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment. Front Biosci (Landmark Ed). 2017;22(3):385-406. DOI: https://doi.org/10.2741/4490
Howe KL, Achuthan P, Allen J, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Azov AG, Bennett R, Bhai J, Billis K. Ensembl. Nucl Acid Res. 2021;49(1):884-91. DOI: https://doi.org/10.1093/nar/gkaa942
Tomanin R, Karageorgos L, Zanetti A, Al‐Sayed M, Bailey M, Miller N, Sakuraba H, Hopwood JJ. Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: review and classification of published variants in the ARSB gene. Human Mut. 2018;39(12):1788-802.
Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. Surv Ophthalmol. 2006;51(1):1-17. DOI: https://doi.org/10.1016/j.survophthal.2005.11.007
Azak E, Gunduz M. Cardiovascular findings and effects of enzyme replacement therapy in patients with mucopolysaccharidosis type VI. Turk Kardiyoloji Dernegi Arsivi. 2019;47:587-93. DOI: https://doi.org/10.5543/tkda.2019.44502
Swiedler SJ, Beck M, Bajbouj M, Giugliani R, Schwartz I, Harmatz P, et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux–Lamy syndrome). Am J Med Gen. 2005;134(2):144-50. DOI: https://doi.org/10.1002/ajmg.a.30579
Giugliani R, Lampe C, Guffon N, Ketteridge D, Leão‐Teles E, Wraith JE, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux–Lamy syndrome)—10‐year follow‐up of patients who previously participated in an MPS VI survey study. American journal of medical genetics Part A. 2014;164(8):1953-64. DOI: https://doi.org/10.1002/ajmg.a.36584
Wood T, Bodamer OA, Burin MG, D'Almeida V, Fietz M, Giugliani R, et al. Expert recommendations for the laboratory diagnosis of MPS VI. Molecular genetics and metabolism. 2012 May 1;106(1):73-82. DOI: https://doi.org/10.1016/j.ymgme.2012.02.005
Tomanin R, Karageorgos L, Zanetti A, Al‐Sayed M, Bailey M, Miller N, et al. Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: review and classification of published variants in the ARSB gene. Human Muta. 2018;39(12):1788-802. DOI: https://doi.org/10.1002/humu.23613
Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, Borgo A, Braunlin E, Eto Y, Gold JI, Jester A. Recommendations for the management of MPS IVA: systematic evidence-and consensus-based guidance. Orphanet J Rare Dis. 2019;14:1-25. DOI: https://doi.org/10.1186/s13023-019-1074-9
Downloads
Published
How to Cite
Issue
Section
